Literature DB >> 24048691

Selective induction of P2Y14 receptor by RANKL promotes osteoclast formation.

Seung Ah Lee1, Jin Hee Park, Soo Young Lee.   

Abstract

The purinergic receptor P2Y, G protein coupled, 14 (P2Y14) receptor for UDP-glucose and other UDP-sugars has been implicated in the regulation of the stem cell compartment as well as neuroimmune function. However, the role of P2Y14 in osteoclast formation is completely unknown. We found that RANKL selectively induced P2Y14 among seven mammalian P2Y receptors when analysed at both the mRNA and protein level, but inhibitors of the mitogenactivated protein (MAP) kinase pathway suppressed induction of P2Y14 proteins. Extracellular addition of UDP-sugars such as UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetyl glucosamine promoted RANKL-induced osteoclastogenesis, while P2Y14 downregulation by RNA interference inhibited osteoclast formation. Taken together, these results suggest that P2Y14 may act as the receptor for UDP-sugars in osteoclast precusors and may regulate RANKL-induced osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24048691      PMCID: PMC3887970          DOI: 10.1007/s10059-013-0226-3

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  31 in total

1.  Extracellular ADP is a powerful osteolytic agent: evidence for signaling through the P2Y(1) receptor on bone cells.

Authors:  A Hoebertz; S Meghji; G Burnstock; T R Arnett
Journal:  FASEB J       Date:  2001-05       Impact factor: 5.191

Review 2.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

3.  Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand.

Authors:  K A Buckley; R A Hipskind; A Gartland; W B Bowler; J A Gallagher
Journal:  Bone       Date:  2002-11       Impact factor: 4.398

4.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

Authors:  Hiroshi Takayanagi; Sunhwa Kim; Takako Koga; Hiroshi Nishina; Masashi Isshiki; Hiroki Yoshida; Akio Saiura; Miho Isobe; Taeko Yokochi; Jun-ichiro Inoue; Erwin F Wagner; Tak W Mak; Tatsuhiko Kodama; Tadatsugu Taniguchi
Journal:  Dev Cell       Date:  2002-12       Impact factor: 12.270

5.  Calcium signalling via multiple P2 purinoceptor subtypes in rat osteoclasts.

Authors:  S H Wiebe; S M Sims; S J Dixon
Journal:  Cell Physiol Biochem       Date:  1999

6.  Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL).

Authors:  M Matsumoto; T Sudo; T Saito; H Osada; M Tsujimoto
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

7.  Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo.

Authors:  Susanne Syberg; Andrea Brandao-Burch; Jessal J Patel; Mark Hajjawi; Timothy R Arnett; Peter Schwarz; Niklas R Jorgensen; Isabel R Orriss
Journal:  J Bone Miner Res       Date:  2012-11       Impact factor: 6.741

Review 8.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

9.  P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells.

Authors:  Byeong-Chel Lee; Tao Cheng; Gregor B Adams; Eyal C Attar; Nobuyuki Miura; Sean Bong Lee; Yoriko Saito; Ivona Olszak; David Dombkowski; Douglas P Olson; Julie Hancock; Peter S Choi; Daniel A Haber; Andrew D Luster; David T Scadden
Journal:  Genes Dev       Date:  2003-07-01       Impact factor: 11.361

Review 10.  Signaling crosstalk between RANKL and interferons in osteoclast differentiation.

Authors:  Hiroshi Takayanagi; Sunhwa Kim; Tadatsugu Taniguchi
Journal:  Arthritis Res       Date:  2002-05-09
View more
  9 in total

Review 1.  UDP-Sugars as Extracellular Signaling Molecules: Cellular and Physiologic Consequences of P2Y14 Receptor Activation.

Authors:  Eduardo R Lazarowski; T Kendall Harden
Journal:  Mol Pharmacol       Date:  2015-03-31       Impact factor: 4.436

2.  Nucleotides modulate synoviocyte proliferation and osteoclast differentiation in macrophages with potential implications for rheumatoid arthritis.

Authors:  Sai Krishna Srimadh Bhagavatham; Vishnu Kannan; V M Datta Darshan; Venketesh Sivaramakrishnan
Journal:  3 Biotech       Date:  2021-11-19       Impact factor: 2.406

3.  Role of UDP-Sugar Receptor P2Y14 in Murine Osteoblasts.

Authors:  Nicholas Mikolajewicz; Svetlana V Komarova
Journal:  Int J Mol Sci       Date:  2020-04-15       Impact factor: 5.923

Review 4.  Small Molecules Enhance Scaffold-Based Bone Grafts via Purinergic Receptor Signaling in Stem Cells.

Authors:  Patrick Frank Ottensmeyer; Markus Witzler; Margit Schulze; Edda Tobiasch
Journal:  Int J Mol Sci       Date:  2018-11-14       Impact factor: 5.923

Review 5.  Signaling of the Purinergic System in the Joint.

Authors:  Carmen Corciulo; Bruce N Cronstein
Journal:  Front Pharmacol       Date:  2020-01-24       Impact factor: 5.810

Review 6.  P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo-inflammation.

Authors:  Lyvia Lintzmaier Petiz; Talita Glaser; Julio Scharfstein; Mariusz Z Ratajczak; Henning Ulrich
Journal:  Stem Cell Rev Rep       Date:  2021-02-11       Impact factor: 5.739

Review 7.  Integration of Sugar Metabolism and Proteoglycan Synthesis by UDP-glucose Dehydrogenase.

Authors:  Brenna M Zimmer; Joseph J Barycki; Melanie A Simpson
Journal:  J Histochem Cytochem       Date:  2020-08-04       Impact factor: 2.479

Review 8.  Control of Macrophage Inflammation by P2Y Purinergic Receptors.

Authors:  Dominik Klaver; Martin Thurnher
Journal:  Cells       Date:  2021-05-04       Impact factor: 6.600

Review 9.  P2Y Receptors in Bone - Anabolic, Catabolic, or Both?

Authors:  Yuhan Zhou; Hector M Arredondo; Ning Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-07       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.